Mark S Huberman

Affiliations

Division of Medical Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.

Publications (2)

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer.

Clinical lung cancer

Avec: Kartik Sehgal , Anushi Bulumulle , Heather Brody , Ritu R Gill , Shravanti Macherla , Aleksandra Qilleri , Danielle C McDonald , Cynthia R Cherry , Meghan Shea , Mark S Huberman , Paul A VanderLaan , Glen J Weiss , Paul R Walker , Daniel B Costa , Deepa Rangachari

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III

JCO precision oncology

Avec: Joel W Neal , Daniel B Costa , Alona Muzikansky , Joseph B Shrager , Michael Lanuti , James Huang , Kavitha J Ramachandran , Deepa Rangachari , Mark S Huberman , Zofia Piotrowska , Mark G Kris , Christopher G Azzoli , Lecia V Sequist , Jamie E Chaft

Réseau de co-auteurs

Daniel B Costa 2 collaborations

Deepa Rangachari 2 collaborations

Kartik Sehgal 1 collaboration

Anushi Bulumulle 1 collaboration

Heather Brody 1 collaboration

Ritu R Gill 1 collaboration

Shravanti Macherla 1 collaboration

Aleksandra Qilleri 1 collaboration

Danielle C McDonald 1 collaboration

Cynthia R Cherry 1 collaboration

Meghan Shea 1 collaboration

Paul A VanderLaan 1 collaboration

Glen J Weiss 1 collaboration

Paul R Walker 1 collaboration

Joel W Neal 1 collaboration

Alona Muzikansky 1 collaboration

Joseph B Shrager 1 collaboration

Michael Lanuti 1 collaboration

James Huang 1 collaboration

Kavitha J Ramachandran 1 collaboration

Zofia Piotrowska 1 collaboration

Mark G Kris 1 collaboration

Christopher G Azzoli 1 collaboration

Lecia V Sequist 1 collaboration

Jamie E Chaft 1 collaboration